Compare · AZN vs MIRM
AZN vs MIRM
Side-by-side comparison of AstraZeneca PLC (AZN) and Mirum Pharmaceuticals Inc. (MIRM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and MIRM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 41.3x MIRM ($6.37B).
- AZN has been more active in the news (13 items in the past 4 weeks vs 12 for MIRM).
- Both have 25 recent analyst ratings on file.
- Company
- AstraZeneca PLC
- Mirum Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $263.10B
- $6.37B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2019
- News (4w)
- 13
- 12
- Recent ratings
- 25
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
Latest MIRM
- SVP, GLOBAL CONTROLLER Howe Jolanda exercised 40,000 shares at a strike of $6.27 and sold $4,000,000 worth of shares (40,000 units at $100.00) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.
- CHIEF FINANCIAL OFFICER Bjerkholt Eric sold $599,510 worth of shares (6,001 units at $99.90) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 36,355 units (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Peetz Christopher sold $1,978,402 worth of shares (20,000 units at $98.92) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $2.94 (SEC Form 4)
- SEC Form 144 filed by Mirum Pharmaceuticals Inc.
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 144 filed by Mirum Pharmaceuticals Inc.
- SEC Form SCHEDULE 13G filed by Mirum Pharmaceuticals Inc.
- SVP, GLOBAL CONTROLLER Howe Jolanda sold $193,734 worth of shares (1,840 units at $105.29) as part of a pre-agreed trading plan, decreasing direct ownership by 59% to 1,274 units (SEC Form 4)
- SEC Form 10-Q filed by Mirum Pharmaceuticals Inc.